Opinion|Videos|January 17, 2025
Sequencing Considerations in Relapsed/Refractory CLL
Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What sequencing considerations influence your choice of upfront therapy for chronic lymphocytic leukemia (CLL), and how do these decisions shape the selection of treatments in the relapsed/refractoryCLL setting?
- How does the treatment sequencing study in CLL/SLL by Rhodes and colleagues, presented at the 2024 American Society of Hematology annual meeting, influence your clinical approach?
Advertisement
Related to this article
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5